Last reviewed 2026-05-14 · How we verify

Non-Vagifem® LDVE, Estradiol

Novo Nordisk A/S · Phase 2 active Small molecule

Non-Vagifem® LDVE, Estradiol is a Small molecule drug developed by Novo Nordisk A/S. It is currently in Phase 2 development.

At a glance

Generic name	Non-Vagifem® LDVE, Estradiol
Sponsor	Novo Nordisk A/S
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Vaginal Estradiol Tablets (Vagifem®) and Endometrial Cancer Risk in the Treatment of Postmenopausal Vaginal Atrophy

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Non-Vagifem® LDVE, Estradiol CI brief — competitive landscape report
Non-Vagifem® LDVE, Estradiol updates RSS · CI watch RSS
Novo Nordisk A/S portfolio CI

Frequently asked questions about Non-Vagifem® LDVE, Estradiol

What is Non-Vagifem® LDVE, Estradiol?

Non-Vagifem® LDVE, Estradiol is a Small molecule drug developed by Novo Nordisk A/S.

Who makes Non-Vagifem® LDVE, Estradiol?

Non-Vagifem® LDVE, Estradiol is developed by Novo Nordisk A/S (see full Novo Nordisk A/S pipeline at /company/novo-nordisk).

What development phase is Non-Vagifem® LDVE, Estradiol in?

Non-Vagifem® LDVE, Estradiol is in Phase 2.

Manufacturer: Novo Nordisk A/S — full pipeline
Compare: Non-Vagifem® LDVE, Estradiol vs similar drugs
Pricing: Non-Vagifem® LDVE, Estradiol cost, discount & access